AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study. (CONTI-PV)

An Open-label, Multicenter, Phase IIIb Study Assessing the Long-term Efficacy and Safety of AOP2014 and Standard First Line Treatment (BAT) in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study

Polycythemia Vera (PV) is a disease of bone marrow stem cells that manifests in a drastic increase of red blood cells and frequently also of white blood cells. The "thickening" of the blood in relation with a modified function of the cells has several consequences like increased blood pressure, pruritus of the skin, fatigue, disturbed blood circulation in the brain as well as fingers and toes and an increased risk of arterial and venous thrombosis (thrombosis is the formation of a blood clot in a vessel); like stroke, cardiac infarction, deep vein thrombosis in the legs. In case of a strong increase of platelets there is an additional risk of bleedings. As the disease progresses the size of spleen and liver increased in most cases and the bone marrow shows signs of fibrosis. In some cases of PV a progression at a later time point to a leukemia (increased formation of white blood cells) can occur.

The aim of this study is to show that the study drug AOP2014 (pegylated proline interferon alpha-2b) has the long term efficacy and safety in controlling the disease. A comparison arm is receiving best available therapy as selected by the investigator. Response to the treatment is measured by several blood parameters as well as size of the spleen.

Interferon-alpha has been shown to be effective in controlling the blood parameters by immunologically influencing the blood building cells. This can lead to a suppression of the disease-causing stem cells and help healthy stem cells to proliferate. Through this mechanism it is possible that Interferon-alpha can avoid long-term damaging effects of the disease.

Study Overview

• Status: Completed
• Conditions: Polycythemia Vera
• Intervention / Treatment: Drug: Best available therapy (BAT); Drug: Pegylated-Proline-interferon alpha-2b

Detailed Description

This is a Phase III, parallel-arm, open-label continuation of the PROUD-PV study performed in adults diagnosed with Polycythemia Vera (PV). Patients who received AOP2014 in the primary study, PROUD-PV will continue on AOP2014, patients who received HU in the PROUD-PV study will receive best available therapy as selected by the investigator. Only patients who completed PROUD-PV including the end of study visit will be enrolled into this continuation study.

• Study Type: Interventional
• Enrollment (Actual): 170
• Phase: Phase 3

Contacts and Locations

Study Locations

• Austria
  • Graz, Austria
    • LKH Graz
  • Innsbruck, Austria
    • University Hospital Innsbruck
  • Linz, Austria
    • Elisabethinen Hospital Linz
  • Salzburg, Austria
    • Salzburg Regional Hospital
  • Vienna, Austria
    • Medical University Vienna
  • Vienna, Austria
    • Hanusch Hospital
  • Wels, Austria
    • Hospital Wels-Grieskirchen
• Bulgaria
  • Plovdiv, Bulgaria
    • University Multiprofile Hospital for Active Treatment "Sveti Georgi", Plovdiv
  • Sofia, Bulgaria
    • Specialized Hospital for Active Treatment of Hematological Diseases
  • Varna, Bulgaria
    • Multiprofile Hospital for Active Treatment "Sveta Marina", Varna
  • Vratsa, Bulgaria
    • Multiprofile Hospital for Active Treatment - Hristo Botev, Vratsa, First Department of Internal Medicine
• Czechia
  • Brno, Czechia
    • University Hospital Brno
  • Hradec Kralove, Czechia
    • University Hospital Hradec Kralove
  • Prague, Czechia
    • University Hospital Motol
  • Prague, Czechia
    • University Hospital Kralovske Vinohrady
• France
  • Marseille, France
    • Institute Paoli-Calmettes
  • Paris, France
    • Hôspital Saint-Louis
  • Poitiers, France
    • Clinical Research Center CIC
• Germany
  • Aachen, Germany
    • Aachen University Hospital, Medical Clinic IV
  • Bonn, Germany
    • University Hospital Bonn, Center for Internal Medicine, Medical Clinic and Outpatient Clinic III
  • Dresden, Germany
    • University Hospital Carl Gustav Carus, Medical Clinic and Polyclinic I
• Hungary
  • Budapest, Hungary
    • St Istvan and St Laszlo Hospital of Budapest
  • Debrecen, Hungary
    • University of Debrecen
  • Gyula, Hungary
    • Bekes County Pandy Kalman Hospital, 1st Department of Medicine, Hematology
  • Kaposvar, Hungary
    • Kaposi Mór County Teaching Hospital
  • Szeged, Hungary
    • University of Szeged, Albert Szent-Gyorgyi Clinical Center, Koranyi fasor 6
• Poland
  • Krakow, Poland
    • University Hospital in Cracow
  • Lublin, Poland
    • Independent Public Teaching Hospital No.1 in Lublin
  • Rzeszow, Poland
    • Fryderyk Chopin Provincial Specialized Hospital
  • Torun, Poland
    • Nicolaus Copernicus Municipal Specialist Hospital
  • Warsaw, Poland
    • Institute of Hematology and Transfusion Medicine
• Romania
  • Brasov, Romania
    • Emergency Clinical County Hospital Brasov
  • Bucharest, Romania
    • Bucharest University Emergency Hospital
  • Bucharest, Romania
    • Coltea Clinical Hospital
• Russian Federation
  • Petrozavodsk, Russian Federation
    • Baranov Republican Hospital
  • Samara, Russian Federation
    • Samara Kalinin Regional Clinical Hospital
  • Syktyvkar, Russian Federation
    • Komi Republican Oncology Center
  • Tula, Russian Federation
    • Tula Regional Clinical Hospital
  • Yaroslavl, Russian Federation
    • Yaroslavl Regional Clinical Hospital
• Slovakia
  • Banska Bystrica, Slovakia
    • University Hospital with Outpatient Clinic F.D. Roosevelt
  • Bratislava, Slovakia
    • Saint Cyril and Metod University Hospital Bratislava
• Spain
  • Barcelona, Spain
    • Hospital Del Mar
• Ukraine
  • Cherkasy, Ukraine
    • Cherkasy Regional Oncology Center, Regional Treatment and Diagnostics Hematology Center
  • Dnipropetrovsk, Ukraine
    • Dnipropetrovsk City Multispecialty Clinical Hospital #4
  • Kiev, Ukraine
    • National Research Center for Radiation Medicine, Institute of Clinical Radiology
  • Lviv, Ukraine
    • Institute of blood pathology and transfusion medicine
  • Zhytomyr, Ukraine
    • O.F. Herbachevskyi Regional Clinical Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Patients who completed the 12 months AOP2014 treatment arm of the PROUD-PV study and at the "end-of-treatment visit" (EoT) of the PROUD-PV study who fulfill at least one of the following criteria:

   • normalization of at least two out of three main blood parameters (Hct, PLTs and WBCs) if these parameters were moderately increased (Hct<50%, WBC<20 x 109/L, PLTs<600 x 109/L) at baseline of the PROUD-PV study, OR
   • >35% decrease of at least two out of three main blood parameters (Hct, PLTs and WBCs) if these parameters were massively increased (Hct>50%, WBCs>20 x 109/L, PLTs>600 x 109/L), at baseline of the PROUD-PV study, OR
   • normalization of spleen size, if spleen was enlarged at baseline of the PROUD-PV study, OR
   • otherwise a clear, medically verified benefit from treatment with AOP2014 (e.g. normalization of disease-related micro-vasculatory symptoms, substantial decrease of JAK2 allelic burden).
2. Signed written ICF.

Exclusion criteria:

Withdrawal criteria, as specified in the PROUD-PV study, which mandate treatment discontinuation:

1. Non-recovery from the AOP2014 related toxicities to the grade (usually, Grade I) which allows continuation of the treatment.
2. HADS score of 11 or higher on either or both of the subscales, and /or development or worsening of the clinically significant depression or suicidal thoughts.
3. Progressive and clinically significant increase of liver enzyme levels despite dose reduction, or if such increase is accompanied by increased bilirubin level, any signs or symptoms of a clinically significant autoimmune disease.
4. Clinically significant development of a new ophthalmologic disorder, or worsening of a pre-existing one, during the study.
5. Loss of efficacy of AOP2014 or any comparable situation where no further benefits of treatment continuation are expected by the investigator.

The main efficacy evaluation criterion will be disease response defined as Hct<45% without phlebotomy (at least 3 months since the last phlebotomy), PLTs<400 x 109/L, WBCs<10 x 109/L, and normal spleen size.

The main efficacy endpoint will be the maintenance rate of disease response at assessment visits (every three months).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Best available therapy (BAT); Best available therapy, as chosen by the investigator for patients who had been on HU in the 1 Year PROUD-PV study	Drug: Best available therapy (BAT); Best available therapy as selected by the investigator; Other Names: best available therapy
Experimental: Pegylated-Proline-interferon alpha-2b; AOP2014 for those patients who had been on AOP2014 in the PROUD-PV study	Drug: Pegylated-Proline-interferon alpha-2b; Subjects will continue to receive the dosage which delivers the optimal disease response (hematocrit [Hct]<45%, platelets [PLTs]<400 x 109/L and leukocytes [WBCs]<10 x 109/L), as determined in the PROUD-PV study, preferably at the level of target blood values.; Other Names: AOP2014

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Disease response at quarterly assessment visits	The primary efficacy endpoint will be the rate of disease response at assessment visits (every 3 months). The co-primary efficacy evaluation criterion will be (1) disease response defined as hematologic response: Hct<45% without phlebotomy (at least 3 months since the last phlebotomy), PLTs<400 x 109/L, WBCs<10 x 109/L, and normal spleen size, and (2) disease response defined as hematologic response (Hct<45% without phlebotomy (at least 3 months since the last phlebotomy), PLTs<400 x 109/L, WBCs<10 x 109/L), resolution and/or clinically improvement of disease-related signs (clinical significant splenomegaly) and disease-related symptoms (microvascular disturbances, pruritus, headache).	3 years

Collaborators and Investigators

• Sponsor: AOP Orphan Pharmaceuticals AG
• Collaborators: PharmaEssentia Corporation (for the U.S.)
• Investigators: Principal Investigator: Heinz Gisslinger, MD, Med Uni Wien

Study record dates

Study Major Dates

• Study Start (Actual): November 1, 2014
• Primary Completion (Actual): April 29, 2021
• Study Completion (Actual): April 29, 2021

Study Registration Dates

• First Submitted: August 14, 2014
• First Submitted That Met QC Criteria: August 14, 2014
• First Posted (Estimate): August 15, 2014

Study Record Updates

• Last Update Posted (Actual): June 1, 2021
• Last Update Submitted That Met QC Criteria: May 27, 2021
• Last Verified: May 1, 2021

More Information

Terms related to this study

• Keywords: Hematologic Diseases; Polycythemia; Bone Marrow Diseases; Interferon-alpha; Myeloproliferative Disorders; Polycythemia Vera; Peginterferon alfa-2b; Pegylated-Proline-interferon alpha-2b (AOP2014); PROUD-PV; CONTINUATION-PV; AOP Orphan
• Additional Relevant MeSH Terms: Neoplasms; Neoplasms by Site; Bone Marrow Diseases; Hematologic Diseases; Myeloproliferative Disorders; Bone Marrow Neoplasms; Hematologic Neoplasms; Polycythemia Vera; Polycythemia; Physiological Effects of Drugs; Anti-Infective Agents; Antiviral Agents; Antineoplastic Agents; Immunologic Factors; Interferons; Interferon-alpha; Interferon alpha-2
• Other Study ID Numbers: CONTINUATION-PV; 2014-001357-17 (EudraCT Number)